Discover Gilead Sciences' significant 8-K filing dated August 10, 2025. Stay informed on crucial developments impacting stock GILD and shareholder interests.
Explore AstraZeneca PLC's latest Form 6-K, filed on August 1, 2025, detailing 1.55B voting rights and compliance with UK regulations vital for shareholders.
AstraZeneca plans to invest $50B in US manufacturing and R&D by 2030, aiming for $80B revenue. This will create tens of thousands of jobs and enhance drug production capabilities.
AstraZeneca's Baxdrostat shows significant promise in treating uncontrolled hypertension, marking a major advancement in cardiovascular medicine.
Explore AstraZeneca PLC's Form 6-K detailing issued share capital, total voting rights, and regulatory compliance for investors and analysts.
AstraZeneca's Form 6-K reveals CEO Pascal Soriot's acquisition of 8,970 shares post-vesting. Key insights on performance, compliance, and tax obligations included.
AstraZeneca PLC's May 2025 Form 6-K details CEO Pascal Soriot's appointment to Agilent Technologies. Explore key insights on leadership changes and regulatory compliance.
Explore Biogen's Q1 2025 financial results, showcasing $2.43B revenue growth, net income decline, and strategic restructuring for future profitability.
Explore key insights from AstraZeneca's 2025 AGM, highlighting shareholder support, board changes, and future outlook. Discover why we recommend a 'Hold' amid market uncertainties.
Explore AstraZeneca PLC's April 2025 financial report detailing voting rights, regulatory compliance, and company overview in the biopharmaceutical sector.
Explore RedHill Biopharma's strategic licensing agreement for RHB-102, targeting a $7.5B antiemetics market. Key insights on financial terms, product details, and market impact.
Explore AstraZeneca PLC's financial report detailing 1.55B voting rights, regulatory compliance, and company overview. Key insights for shareholders and stakeholders.